Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Linked to Faulty Molecular Signaling in Brain Disorders

By LabMedica International staff writers
Posted on 17 Feb 2009
A team of molecular neurobiologists has found that a specific microRNA plays a key role in the development of a number of brain disorders including schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), mood disorders, and other psychiatric illnesses. More...
These syndromes all result from a disruption in the function of N-methyl-D-aspartate (NMDA) glutamate receptors, which are regulators of rapid neurotransmission and synaptic plasticity.

Investigators at Scripps Florida (Jupiter, FL, USA) used both chemical and genetic tools to study the molecular mechanisms associated with NMDA-related behavior problems in mouse models. A population of normal mice was treated with dizocilpine, a known NMDA antagonist that has been reported to cause changes in human patients that resemble acute psychosis. A second study group comprised mice with a mutation in the Grin1gene, which results in a substantial decrease in NMDA expression levels.

Results published in the February 5, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) revealed that disruption of NMDA receptor signaling by either chemical or genetic means reduced levels of the brain-specific microRNA, miR-219, in the prefrontal cortex (PFC) of the mice. The PFC is the area of the brain associated with memory, personality, and decision-making.

Further results showed that miR-219 targeted a key component of the NMDA signaling cascade, CaMKII-gamma, a calcium/calmodulin-dependent protein kinase. MiR-219 depressed the levels of CaMKII-gamma in vitro, while inhibition of miR-219 with specific antibodies in vivo altered its expression. Calcium is an integral component of the signal transduction pathway, where it modulates release of neurotransmitters from neurons. A disruption of calcium flow through NMDA would interfere with normal synaptic plasticity, a situation common to a number of brain disorders.

"We have shown the involvement of miR-219 in the signaling cascade, and with this important calcium kinase, and that makes miR-219 even more of a target of interest for potential drug development," said senior author Dr. Claes Wahlestedt, professor of molecular neurosciences at Scripps Florida. "These two facts alone mean that we should look at this microRNA far more than we have in the past."

"In the study we asked the question, which noncoding RNA players might have something to do with NMDA signaling in the prefrontal cortex part of the brain?" said Dr. Wahlestedt. "As we discovered, miRNA-219, which is a brain-specific microRNA, plays an integral part in the NMDA signaling process. Our findings strongly support the idea that this previously uncharacterized microRNA significantly modulates NMDA signaling and associated behavioral problems."

Related Links:

Scripps Florida




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.